In mammalian cells, the level of estrogen receptor A (ERA) is rapidly decreased upon estrogen treatment, and this regulation involves proteasome degradation. Using different approaches, we showed that the Mdm2 oncogenic ubiquitinligase directly interacts with ERA in a ternary complex with p53 and is involved in the regulation of ERA turnover (both in the absence or presence of estrogens). Several lines of evidence indicated that this effect of Mdm2 required its ubiquitin-ligase activity and involved the ubiquitin/proteasome pathway. Moreover, in MCF-7 human breast cancer cells, various p53-inducing agents (such as UV irradiation) or treatment with RITA (which inhibits the interaction of p53 with Mdm2) stabilized ERA and abolished its 17B-estradioldependent turnover. Interestingly, our data indicated that ligand-dependent receptor turnover was not required for efficient transactivation. Altogether, our results indicate that the Mdm2 oncoprotein and stress-inducing agents complexly and differentially regulate ERA stability and transcriptional activity in human cancer cells. [Cancer Res 2007;67(11):5513-21] 
Introduction
Estrogens are key regulators of cell differentiation and proliferation, and these hormones play important roles in female reproduction physiology and tissue homeostasis. They exert their biological action via specific receptors (ERa and ERh), which are members of a superfamily of hormone nuclear receptors, acting as gene regulatory transcription factors (1) . Upon ligand binding, ERs regulate gene expression through the binding to their cognate estrogen response elements (ERE) or via protein-protein interactions with transcription factors such as activator protein-1 or specificity protein-1. In the presence of hormone, ERs undergo a major conformational change allowing the recruitment of transcriptional cofactor complexes, which in turn engage the basal transcription machinery and/or act to locally modify chromatin structure and subsequently stimulate expression of estrogenresponsive genes.
Liganded nuclear receptors recruit various types of enzymatic activities that participate in gene expression regulation (2) . Previous studies have suggested that ubiquitin-conjugating enzymes or ubiquitin-protein ligases, such as UbcH5/UbcH7 (3, 4) , RPF1/RSP5 (5) , or E6-AP (6) , interact with members of the nuclear receptor superfamily and modulate their transactivation functions. Similarly, ATPase subunits of the proteasome complex, such as TRIP1/SUG1 (7) or TBP1 (8) , also bind nuclear receptors and modulate their functions.
More than 30 years ago, Jensen et al. have shown that 17hestradiol (E2) treatment significantly reduces ERa levels in the uterus of ovariectomized rats (9) . More recently, several studies have shown that binding of E2 to ERa significantly decreases its stability. This shorter half-life in the presence of hormone seems to implicate the ubiquitin/proteasome pathway because ERa has been shown to be ubiquitinated (10) , and the ligand-dependent down-regulation is blocked by proteasome inhibitors (3, 11, 12) . Interestingly, although partial antiestrogens, such as tamoxifen, also increase ERa accumulation, pure antihormones, such as the ICI 182,780 compound, strongly decrease receptor stability (10, 13) . Several reports have suggested that the proteasome may control not only ERa protein levels but also hormone-dependent transcription (14) . This effect is associated with the immobilization of ERa on the nuclear matrix as determined by fluorescence recovery after photobleaching (15) . Although several candidates have been proposed to account for the E2-dependent regulation of ERa expression, the exact molecular mechanisms still remain unraveled.
The Mdm2 oncogene is overexpressed in a wide variety of human cancers (16) , and its role in tumorigenesis is linked to its ability to act as an E3 ubiquitin-ligase (17) , which mediates the ubiquitination and proteasome-dependent degradation of several growth regulatory proteins including p53 (18, 19) . Interestingly, it has been previously suggested that Mdm2 could directly interact with ERa (20, 21) , and a positive effect of Mdm2 overexpression on ERa activity has also been reported (20) .
In the present study, we show that the Mdm2 oncoprotein is involved in both ligand-dependent and ligand-independent decrease of ERa stability. Our data indicate that Mdm2 regulates ERa expression as a ternary complex with p53, and in support of this observation, we show that various stress-inducing agents (which stabilize p53) block E2-dependent regulation of ERa stability in MCF-7 human breast cancer cells. Finally, this study provides several lines of evidence showing that the E2-dependent turnover of the receptor is not necessary for ERE-mediated transactivation.
described elsewhere. The GST-p53 and the pcDNA3 plasmids encoding fulllength p53 (25) were obtained from U. Hibner [Institut de Génétique Moléculaire de Montpellier (IGMM), Montpellier, France]. The pXJ-Mdm2 vector was obtained from B. Wasylyk (IGBMC), and the pcMI-Hdm2 contained the Mdm2 cDNA (BamHI/EcoRI fragment) subcloned into the pCMI1 vector (26) . The pcMI-Hdm2DRING was obtained by inserting into the pCMI1 vector a PCR-amplified BamHI/EcoRI fragment corresponding to amino acids 1 to 435. The GST-Mdm2 was constructed by cloning a XhoI/NotI fragment of the human Mdm2 cDNA into the pGEX4T3 vector (Amersham Biosciences). The Gal-Mdm2 was generated by introducing a blunted NcoI/BglII fragment from pXJMdm2 into the SmaI site of the pSG424 plasmid (27) . The RITA compound (NSC652287) was obtained from Dr. R.J. Schultz (NIH, Developmental Therapeutics Program, Drug Synthesis and Chemistry Branch, Rockville, MD).
Cell culture. Monolayer cell cultures (MCF-7, HeLa, and BG1) were grown, respectively, in Ham's F-12/Dulbecco's modified Eagle's medium (1:1, F12/DMEM) or DMEM alone supplemented with 10% FCS (Invitrogen) and antibiotics. Before hormonal treatments, cells were stripped of endogenous estrogens as previously described (28) . When indicated, cells were irradiated using a Stratalinker UV cross-linker (model 1800) from Stratagene. The MELN cell line derived from MCF-7 cells stably transfected with the ERE-hGlob-Luc-SVneo plasmid (29) . Mouse embryo fibroblasts (MEF) null for both p53 and Mdm2 (MEFdKO; ref. 30) were obtained from G. Lozano (Houston, TX) and cultured in F12/DMEM. Transient transfection and luciferase assays. Cells were plated in sixwell plates (10 5 per well) 24 h before DNA transfection (4 Ag of total DNA) by the calcium phosphate method using CMV-hGal expression vector as an internal control. Luciferase values from transient transfection were normalized by the h-galactosidase activities as described (28) , and all data were expressed as mean F SD.
Western blot analysis. Whole-cell extracts were prepared in high-salt lysis buffer (HSB) containing 500 mmol/L NaCl, 50 mmol/L Tris (pH 8), 1% NP40, 1 mmol/L DTT, and proteases inhibitors (Roche Diagnostics). Proteins were quantified using the Bradford assay (Bio-Rad Laboratories), and 30 Ag were usually loaded on SDS-PAGE and transferred to polyvinylidene difluoride membrane. Blots were saturated in TBST buffer [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 0.1% Tween 20 (v/v), 5% nonfat dehydrated milk (w/v)]; incubated with specific primary antibodies for ERa, Figure 1 . Interaction of ERa with p53 and Mdm2. A, GST pull-down assays were carried out as described in Materials and Methods using bacterially expressed GST, GST-Mdm2, or GST-LBD proteins to retain 35 S-labeled ERa or Mdm2 in the presence of vehicle (C ), E2 (10 À6 mol/L), or 4-hydroxytamoxifen (OHT; 10 À6 mol/L). B, schematic representation of the ERa mutants. In vitro translated full-length ERa or various deletion mutants were analyzed for their interaction with the GST-Mdm2 fusion protein.
Inputs, 10% of the material used in the assay (as in A ). C, ERa and Mdm2 expression vectors were transfected into p53/Mdm2 +/+ U2OS cells (lanes 1 and 2 ) or p53/Mdm2 À/À MEFs (MEFdKO; lanes 3 and 4). MCF-7 cells were transfected with p53 and Mdm2 expression vectors (lanes 5-7 ). Whole-cell extracts were subjected to immunoprecipitation as described in Materials and Methods using anti-Mdm2 antibody (lanes 2 and 4), anti-ERa (lane 6), or with an irrelevant antibody (lane 7). Western blotting using either anti-Mdm2, anti-ERa, or anti-p53 antibody was done as indicated. Whole-cell extracts (lanes 1, 3 , and 5 ). Inputs, 10% (left ) and 6% or 18% (respectively, for ERa and for p53/Mdm2; right ). D, mammalian two-hybrid assay was carried out using E2-treated MCF-7 cells transfected with the 17M 5 -Luc reporter together with expressing vectors for Gal4, Gal-GRIP1, or Gal-Mdm2 with VP16 or ER-VP16, in the presence or not of p53. Luciferase activity was expressed as % control in presence of Gal4. Columns, mean of three values; bars, SD. *, P < 0.05 (using Student's t test).
p53, or ubiquitin (Tebu), Mdm2 (clone 2A10; gift from J. Piette, IGMM), pS2 (clone p2802; gift from M.C. Rio, IGBMC), or actin (Sigma); and probed with the appropriate secondary antibody (Sigma). Detection was done using the Chemiluminescence Reagent Plus kit (Perkin-Elmer Life Science).
Immunoprecipitation experiments. Transfected MCF-7 or HeLa cells were lysed either in HSB for ubiquitination detection or in NETN buffer for coimmunoprecipitation. Immunoprecipitations were carried out using anti-ERa or anti-Mdm2 antibody (clone 4B11; gift from J. Piette) and protein G+ agarose beads (Tebu). Beads were washed four times in lysis buffer and boiled in 2Â SDS sample buffer.
GST pull-down assays. In vitro translation and glutathione S-transferase (GST) pull-down assays were done as previously described (28) . Protein interactions were analyzed by SDS-PAGE followed by quantification using a Phosphorimager (Fujix BAS1000).
Apoptosis assay and quantitative PCR. These assays have been described elsewhere (31) .
Results
ERA is involved in a ternary complex with p53 and Mdm2. To better characterize protein-protein interactions between Mdm2 and ERa, we first did GST pull-down experiments. As shown in Fig. 1A (left), we observed a ligand-independent interaction of in vitro translated ERa with Mdm2 expressed as a fusion protein with GST, whereas no detectable interaction was obtained with GST alone. The binding of Mdm2 to ERa was mediated by the ligand-binding domain (LBD) of the receptor, as shown by the recruitment of in vitro expressed Mdm2 by the GST-LBD protein, which was also unaffected by E2 (right). Moreover, the use of a GST-LBD mutated in the conserved AF2 activation domain indicated that this interaction did not require an intact AF2 transactivation domain (data not shown). The use of ERa deletion mutants (shown in Fig. 1B , left) confirmed that both the DBD (HE11 mutant) and the NH 2 -terminal region (HE19 mutant) were not necessary for the binding to Mdm2 (Fig. 1B, right) . By contrast, our data confirmed that the COOH-terminal LBD of ERa was required for the in vitro interaction because the HE15 mutant poorly associated with GST-Mdm2. Altogether, these results showed a direct ligand-and AF-2-independent interaction of ERa with Mdm2.
To confirm that these interactions also occurred in intact cells, we first set up coimmunoprecipitation experiments. As illustrated in Fig. 1C , ERa was found associated with immunoprecipitated Mdm2, as determined by probing the Western blot with a polyclonal antibody specific for the receptor (lanes 1 and 2). Interestingly, when the same experiment was carried out in MEFdKO embryonic fibroblasts (32) derived from p53 À/À and Mdm2 À/À mice (lanes 3 and 4), ERa was not coprecipitated with Mdm2, suggesting that p53 could be required for the interaction between ERa and Mdm2. Indeed, the formation of a ternary complex among ERa, p53, and Mdm2 was further shown by coimmunoprecipitation of both p53 and Mdm2 with endogenous ERa from MCF-7 cells (Fig. 1C, right) .
Moreover, the fact that ERa could be engaged in a ternary complex with p53 and Mdm2 was also confirmed using a modified mammalian two-hybrid system (Fig. 1D ). An expression plasmid coding for Mdm2 fused to the Gal4 DBD (Gal-Mdm2) was cotransfected in MCF-7 cells together with a Gal4-responsive reporter plasmid and an expression vector coding for ERa fused to the VP16 activation domain or for VP16 alone. In our experimental conditions, a slight but significant increase in luciferase activity (>2-fold versus 7-fold with Gal-GRIP used as a positive control) was obtained when ER-VP16 was coexpressed with Gal-Mdm2 (compared with the activity obtained with VP16 alone). Interestingly, when a p53 expression plasmid was cotransfected with Gal-Mdm2 and ER-VP16, we observed a significant increase in luciferase activity (>8-fold), suggesting that p53 indeed stabilize the interaction between ERa and Mdm2. Altogether, these results suggest that ERa, p53, and Mdm2 coexist within the same protein complex in intact cells.
p53 and Mdm2 are required for ligand-dependent ERA turnover. To evaluate the role of Mdm2 and p53 in a liganddependent down-regulation of ERa, we first used the MEFdKO model (32) . As shown in Fig. 2A , in this p53/Mdm2 À/À background, estrogen treatment did not decrease ERa accumulation (as observed in parallel in p53/Mdm2 +/+ wild-type MEFs) but instead slightly increased receptor levels. To show that the expression of p53 and Mdm2 was required for the E2-dependent inhibition of ERa accumulation, we transiently transfected the expression vectors for both p53 and Mdm2 together with the expression vector for ERa in p53/Mdm2 À/À MEFs (Fig. 2B ). In this condition, we not only abolished the positive effect of E2 on ERa accumulation that we observed in control p53/Mdm2 À/À cells, but we also restored the negative hormonal regulation of ERa expression.
Mdm2 regulates ligand-independent expression of ERA. Because some of the data shown in Fig. 1 suggested that Mdm2 could also bind ERa in an E2-independent manner, we investigated the effect of Mdm2 overexpression on ERa accumulation in the absence of ligand. As shown in Fig. 2C (top), when increasing amounts of Mdm2 expression vectors were transiently cotransfected with ERa in untreated HeLa cells, the accumulation of the receptor was significantly decreased. This effect involved the ubiquitin/proteasome pathway because the Mdm2-dependent down-regulation of ERa was completely relieved by the proteasome inhibitor MG132 (Fig. 2C, bottom) . To emphasize the importance of Mdm2 in ligand-independent turnover of ERa, we measured the effect of Mdm2 overexpression on the apparent stability of the ERa protein by chase experiment in HeLa cells using cycloheximide as a protein synthesis inhibitor. As shown in Fig. 2D , we noticed a significant decrease in ERa apparent stability in the presence of Mdm2. This effect of Mdm2 on ERa stability was also observed in the presence of E2 (data not shown), thus emphasizing the role of Mdm2 in the E2-dependent and E2-independent posttranslational regulation of ERa expression.
Mechanisms involved in Mdm2 regulation of ERA stability. To further decipher the molecular mechanisms involved in ERa degradation by Mdm2, we first used a mutant of Mdm2 (Mdm2DRING) deleted in the COOH-terminal part of the protein, which contains the RING domain required for its ubiquitin-ligase activity (33) . As shown in Fig. 3A , this mutant still interacted with ERa in GST pull-down experiment. Interestingly, overexpression of the Mdm2DRING mutant did not decrease ERa accumulation compared with the effect of its wild-type counterpart (Fig. 3B ), suggesting that the E3 ubiquitin-ligase activity of Mdm2 is directly involved in ERa degradation. The implication of the ubiquitin/ proteasome pathway was further shown in ubiquitination assays. As shown in Fig. 3C , after immunoprecipitation of ERa, slowly migrating forms of the receptor were detected both using anti-ERa (bottom) or anti-ubiquitin (top) antibodies, thus confirming that the level of ERa ubiquitination increased upon Mdm2 overexpression. ; lanes 3 and 6) . Cells were treated with E2 (10 À8 mol/L, lanes 2 and 5) or with vehicle alone (lanes 1, 3, 4 , and 6 ). The expression of ERa and Mdm2 was analyzed by immunoblotting. The same experiment was done using the wild-type receptor or the HE11 ERa mutant (deleted of the DBD).
Finally, in an attempt to compare the E2-dependent turnover of the receptor with the ligand-independent degradation observed upon Mdm2 overexpression, we used a mutant of ERa deleted in the central DNA-binding domain involved in the binding of p53 (see Fig. 1B ). 4 This ERa-DDBD mutant (HE11) was no longer degraded upon E2 stimulation (Fig. 3D, lane 5) in support with the role of this domain in recruiting p53 and consistent with the formation of a ternary complex among the receptor, p53, and Mdm2 (Fig. 1) . By contrast, the ligand-independent increase in ERa turnover observed upon Mdm2 overexpression was comparable for the wild-type protein and the DBD-deleted mutant (Fig. 3D, lane 3 for ERa wild type and lane 6 for HE11). Altogether, these data support the hypothesis that different mechanisms might be involved in the regulation of ERa turnover upon E2 treatment or Mdm2 overexpression.
Stress-inducing agents block ligand-dependent turnover of ERA. Previous studies reported that in MCF-7 human breast cancer cells, the E2-dependent decrease of ERa accumulation was abolished by the MG132 proteasome inhibitor (3, 11, 12) . Results shown in Fig. 4A confirmed that MG132 was able to reverse the effect of various ligands, such as E2, estrone (E1), estriol (E3), or diethylstilbestrol, on ERa levels in MCF-7 cells. Interestingly, proteasome blockade is a cellular stress that increased accumulation of p53 (Fig. 4A, compare right and left) and, consequently, induced apoptosis, as shown by quantification of cytoplasmic nucleosomes (Fig. 4B ).
Based on our results concerning the role of Mdm2 in the regulation of ERa turnover, we thought that the effect of MG132 could be linked (at least in part) to its ability to dissociate Mdm2 from p53 and/or ERa. We therefore analyzed the effect of other stress-inducing agents (genotoxic or non-genotoxic) for their ability to regulate E2-dependent turnover. As shown in Fig. 4B , both UV irradiation and inhibition of transcription (actinomycin D treatment) increased significantly programmed cell death in MCF-7 cells. In all conditions, the accumulation of p53 was significantly increased to levels comparable with those obtained after MG132 treatment and, very interestingly, both treatments that increase p53 levels concomitantly suppressed the hormone-dependent down-regulation of ERa (Fig. 4C ).
We then characterized the effect of UV irradiation on the regulation of ERa accumulation. We first showed that the blockade of E2-dependent turnover after UV exposition was rapid since observed 4 h after irradiation and still detectable 24 h later (data not shown). We then investigated the effect of UV irradiation on the response to antiestrogens, which have also been shown to regulate ERa expression. Indeed, as previously reported, incubation with the partial antagonist 4-hydroxytamoxifen increased the level of ERa, whereas pure antiestrogens, such as the ICI 182,780 molecule, negatively regulated the accumulation of the receptor (10) . As shown in Fig. 4D , UV irradiation did not affect the stabilization of ERa upon 4-hydroxytamoxifen treatment. Very interestingly, it did not antagonize the effect of ICI 182,780, whereas it completely reversed the agonist-dependent decrease of ERa levels. This suggested that degradation of ERa by pure antiestrogens involved different mechanisms than those required for hormone-dependent degradation.
Concomitant stabilization of ERA and p53 by stressinducing agents. To confirm that UV irradiation modulated the stability of the ERa protein, we did chase experiments with cycloheximide. As shown in Fig. 5A and B , the stability of the 4 Our unpublished results. receptor in the absence of de novo protein synthesis decreased upon E2 treatment, and UV irradiation completely inhibited the hormone-dependent degradation. As expected, upon UV treatment, p53 seemed very stable, and its accumulation was strongly increased (Fig. 5A) . Altogether, these data suggest that stressinducing agents induce a co-stabilization of p53 and ERa in MCF-7 breast cancer cells. Our hypothesis was that disruption of the p53/ Mdm2/ERa complex upon cellular stress was at the basis of the loss of E2-dependent turnover of the receptor.
To further emphasize this point, we used the NSC652287 compound, also known as RITA (which stands for reactivation of p53 and induction of tumor cell apoptosis) and recently described as an inhibitor of the p53/Mdm2 interaction (34) . As shown in Fig. 5C , treatment of MCF-7 cells with RITA at 1 Amol/L significantly abolished the ligand-dependent decrease in ERa accumulation. This effect was detectable 4 h after the beginning of the treatment and very interestingly, it correlated again with the increase in p53 accumulation. As a control of UV irradiation and RITA treatment, we checked by quantitative reverse transcription-PCR that no up-regulation of the ERa mRNA was associated with the blockade of the E2-dependent decrease observed at the protein level (data not shown). Combined, these data therefore suggest that dissociation of the p53/Mdm2/ERa complex upon cellular stress leads to a co-stabilization of p53 and ERa proteins.
Dissociation between ligand-dependent ERA expression and transactivation. Because previous studies proposed that the E2dependent decrease of ERa accumulation was required for transcriptional activity of the receptor (14), we analyzed whether these two variables were indeed linked in our hands. We first investigated the ability of transiently transfected ERa to increase the transcription of a reporter gene in MEFs expressing or not p53/Mdm2. As shown in Fig. 6A , we found that ERa strongly activated transcription in cells where E2 up-regulated its accumulation (Control). Very interestingly, we found that overexpression of p53/Mdm2 only slightly modify ERa transactivation although it completely inversed the effect of E2 on its accumulation (see Fig. 2B ).
We then analyzed the effect of UV irradiation on endogenous ERa activity. To this aim, we used MELN cells that are MCF-7 cells stably transfected with an E2-regulated luciferase reporter gene, allowing easy monitoring of endogenous ERa activity (24) . MELN cells were treated with E2 4 h after irradiation by UV (i.e., when E2-dependent turnover of ERa was no longer detectable; see Fig. 4 ). As shown in Fig. 6B , the transcriptional activity of ERa was significantly increased both in the absence of ligand or in the presence of E2. In all conditions, the induction by E2 was detectable, confirming that E2-dependent turnover was not a prerequisite for transactivation even on endogenous ERa. Moreover, the same results were obtained on the endogenous E2regulated pS2 gene (Fig. 6C) , thus confirming the dissociation of stress-inducing agents on the accumulation of ERa and on its transactivation.
Finally, we screened several ERa-expressing human cancer cell lines for the negative E2-dependent regulation of ERa accumulation. As shown in Fig. 6D , we found that BG1 ovarian cancer cells exhibited a strong positive regulation of ERa levels in response to E2 treatment, contrasting with the negative regulation observed in MCF-7 breast cancer cells (see Figs. 4 and 5) . Of interest, when we analyzed the transactivation properties of ERa in these two cell lines, we found that at least on the reporter that we used in transient transfection, the respective endogenous receptors were able to transactivate to similar extent (Fig. 6D) . Altogether, our results strongly suggest that the effect of E2 on ERa turnover could be dissociated from its effect on transcriptional activation at least on some target promoters.
Discussion
Modulation of ERa levels is a critical variable in determining the hormonal response of breast cancer cell proliferation. The control of ERa expression is under a complex regulation that takes place both at the transcriptional and posttranscriptional levels. Previous data suggested that ERa was down-regulated in the presence of E2 on January 30, 2020. © 2007 American Association for Cancer cancerres.aacrjournals.org Downloaded from through a proteasome-dependent mechanism (3, 11, 12) . In this study, we have investigated the mechanisms regulating the hormone-induced ERa turnover, and several lines of evidence indicate that Mdm2, an oncogenic ubiquitin-ligase, plays an important role in the regulation of ERa accumulation by E2.
First, using coimmunoprecipitation and a modified two-hybrid assay, we show that Mdm2 interacted with ERa in a ternary complex with p53. The direct in vitro interaction between the receptor and both Mdm2 and p53 was also shown using GST pull-down assays. Our data suggested that Mdm2 binding involved the LBD of ERa but did not require the ligand-dependent AF2 interface. Interestingly, p53 interacted with a different region of the receptor (i.e., the central region; data not shown), thus supporting the formation of a ternary complex.
The use of p53/Mdm2 À/À cells showed that the two proteins were required for the E2-dependent down-regulation of ERa. Moreover, we showed that the COOH-terminal region of Mdm2, which encompassed the E3 activity, was required for the degradation of ERa and that overexpression of Mdm2 increased ERa ubiquitination. Previous studies highlighted the role of the Mdm2 ubiquitin-ligase in the degradation of steroid hormone nuclear receptors. In the case of the glucocorticoid receptor (GR), Sengupta and Wasylyk showed that disruption of the p53/Mdm2 interaction prevented ubiquitination of GR and that the liganddependent trimeric complex between GR, p53 and Mdm2 enhanced proteasomal degradation of the receptor (35) . Moreover, the E3 ligase activity of Mdm2 was also necessary for the ubiquitination and degradation of the androgen receptor (36) .
From the data presented in our study, we propose that p53 and Mdm2 are involved in the ligand-dependent degradation of ERa. Interestingly, in support of our data, it has been recently shown, by chromatin immunoprecipitation, that Mdm2 was recruited on the ERa-regulated pS2 promoter upon E2 stimulation (37, 38) . Moreover, both Mdm2 and p53 expression levels are increased by E2 in MCF-7 breast cancer cells (39) . This positive regulation could be of importance in the E2-dependent down-regulation of the receptor. Obviously, other factors associated with p53 or Mdm2 could be involved in such a degradation complex. A strong candidate is the coactivator AIB1, which has been shown to interact with p53 (40) and to be required for the E2-dependent turnover of ERa (41) . The involvement of AIB1 could explain why the AF2-mutated ERa is no longer degraded upon hormone stimulation. 5 Interestingly, in breast cancer, AIB1 amplification correlates with that of Mdm2 (42) , and AIB1 expression is regulated by ubiquitination (43) .
Our results dealing with the effect of stress-inducing agents on ERa expression clearly indicated that the increased turnover of the receptor in the presence of the pure antiestrogen ICI 182,780 involves different mechanisms than those implicated in the E2dependent degradation. Indeed, the effect of ICI182,780 on ERa levels were not abolished in UV-irradiated MCF-7 cells ( Fig. 4D ) and in MEFdKO (data not shown). Similar dissociation between the effects of E2 and ICI 182,780 were previously reported (44) , and other pathways involving, for example, the NEDD8 ubiquitin-like protein (45) or CSN5/Jab1 (46) could account for the degradation in the presence of pure antihormones.
Previous data have highlighted the existence of a ligandindependent degradation of ERa and showed the role of CHIP (COOH terminus of Hsc70-interacting protein) in the ubiquitination of misfolded ERa (47) . More recently, E6-AP has also been Figure 6 . E2-dependent transactivation of ERa does not require receptor turnover. A, MEFdKO cells were transiently transfected either with the 17Eh-Luc reporter plasmid (300 ng) and ERa (100 ng) alone or together with p53 and Mdm2 expression vectors (same transfection experiment as for the Western blot analysis in Fig. 2B ). Cells were treated with vehicle or E2 (10 À8 mol/L), and the luciferase activity was quantified as described in Materials and Methods. Results were expressed relative to control in presence of ERa alone (% control). Columns, mean of three values; bars, SD. B, MCF-7 cells stably transfected with ERE-hGlob-Luc (MELN cells) were treated with vehicle (control) or E2 (10 À8 mol/L) for 20 h, 4 h after irradiation (UV) or without being irradiated (C ). Luciferase activity was measured as described in Materials and Methods. Columns, mean relative activity (% E2 without irradiation) of three values; bars, SD. C, MCF-7 cells were UV irradiated (150 J/m 2 ) or not (control) in the presence (E2, 10 À8 mol/L) or in the absence (C ) of E2 for 20 h. pS2, p53, and actin protein levels were analyzed by Western blot. D, left, BG1 ovarian cancer cells were treated or not (C ) for 20 h with E2 (10 À8 mol/L), and ERa protein levels were analyzed by Western blot. Right, MCF-7 and BG1 cells were transiently transfected with ERE-hGlob-Luc, treated with vehicle or E2 (10 À8 mol/L), 4-hydroxytamoxifen (10 À8 mol/L) or ICI 182,780 (10 À8 mol/L) for 20 h, and the luciferase activity was quantified and expressed as in (A ).
shown to be involved in a calmodulin-dependent degradation pathway of ERa (48) . Our data suggest that, when overexpressed, Mdm2 is also involved in the ligand-independent turnover of ERa. In these conditions, several evidences indicate that p53 could be dispensable for the effect of Mdm2, and this could reflect the fact that, upon overexpression of Mdm2, the binding equilibrium between ERa and Mdm2 could be strongly displaced towards complex formation, thus avoiding the requirement for p53 to stabilize the interaction. Finally, although we show that Mdm2 increased ERa ubiquitination, further work will be required to define which particular lysine residues are modified by Mdm2 in the presence or absence of E2.
The present work also highlights the regulation of ERa expression by cellular stress. We show that several stress-inducing agents that stabilize p53 also increase ERa levels and block its E2-dependent down-regulation. The stabilization of p53 upon treatment with stress-inducing agents results from its dissociation from Mdm2 due to posttranslational modifications such as phosphorylation (49) . It is interesting to note that phosphorylation of nuclear receptors has also been linked to their turnover (36, 50, 51) . Concerning ERa, it has very recently been reported that S118 is an essential determinant of ERa degradation (38) , and a previous work has shown that extracellular signal-regulated kinase 7 enhances the destruction of the receptor in a ligand-independent manner (52) . By contrast, another report suggests that in MCF-7 cells, inhibition of mitogen-activated protein kinase results in an increased degradation of ERa (53) . Altogether, these data suggest that phosphorylation is directly or indirectly involved in ERa turnover. Interestingly, we found that the degradation observed upon Mdm2 overexpression was no longer detected when we tested ERa mutated on the phosphorylated Ser 118 residues (data not shown).
Finally, although it has been suggested that the E2-dependent turnover of ERa was required for efficient transactivation of the receptor (14) , the data presented herein do not support such a conclusion. We first show that in p53/Mdm2 À/À cells where E2 treatment led to an increase in ERa accumulation, a strong hormone-dependent transactivation was observed. Interestingly, the same result was obtained with endogenous ERa in BG1 ovarian cancer cells. In addition, in MCF-7 cells, the blockade of ERa E2-dependent degradation upon UV irradiation (or MG132; data not shown) did not abolish the transcriptional response to E2 cells both on a stably transfected ERE-containing reporter gene and on the well-known pS2 target gene. Altogether, the present work dissociates the effect of E2 on ERa turnover from the effect of hormone on transactivation, thus supporting previous studies done using MG132, which suggested that the two events are not linked (54) .
In conclusion, we propose that within a same protein complex, ERa and p53 are both targeted by the Mdm2 E3 ubiquitin ligase; consequently, the stability of ERa and p53 is concomitantly increased in response to stress-inducing agents. This study therefore emphasizes the relevance of protein-protein interactions among nuclear receptors, the Mdm2 oncogene, and the p53 tumor suppressor. Several physiologic and pathologic consequences of these interactions have been proposed for the glucocorticoid receptor (55) . Our data showing the involvement of the Mdm2 oncoprotein in the regulation of ligand-dependent and ligandindependent ERa expression are in accordance with a recent study that reported that Mdm2 protein expression is a negative prognostic marker in breast carcinoma whose expression showed a negative correlation with ERa (56) . Such an inverse association might seem surprising because this receptor is believed to mediate proliferative signaling of estrogens. However, our laboratory has shown that in the absence of ligand, ERa also exerts anti-invasive activity in breast cancer cell lines (57) , and this effect could therefore be lowered in tumor cells overexpressing Mdm2. Altogether, the present work highlights the role of Mdm2 on hormone signaling and will be at the basis of future investigations to decipher its importance in various physiopathologic situations.
